1 week ago
Glaukos Corp (NYSE:GKOS) reported mixed results for the fourth quarter on Tuesday.
The company posted quarterly losses of 28 cents per share which missed the analyst consensus estimate of losses of 20 cents per share. The company reported quarterly sales of $143.100 million which beat the analyst consensus estimate of $136.396 million.
Glaukos affirmed FY2026 sales guidance of $600.000 million to $620.000 million.
“Our record fourth quarter results cap off a highly successful year of global execution across our key commercial and development initiatives, leaving us well positioned to sustain our strong growth momentum in 2026 and beyond driven by two transformational growth drivers in iDose TR and now Epioxa,” ...
